MRK

Merck & Co Inc  (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations…

Merck & Co Inc  (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice…

Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged…

Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical…

Merck (NYSE: MRK) announced the acquisition of privately-held biopharma company OncoImmune for an upfront payment of $425 million in cash…

Merck & Co. Inc. (NYSE: MRK) Q3 2020 earnings call dated Oct. 27, 2020 Corporate Participants: Peter Dannenbaum — Vice President, Investor…

Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings and sales for the third quarter of 2020. The…

Merck & Co., Inc. (NYSE: MRK) Q2 2020 earnings call dated July 31, 2020 Corporate Participants: Peter Dannenbaum — Vice President of…

Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of…

Merck & Co (MRK) Q1 2020 earnings call dated April 28, 2020 Corporate Participants: Peter Dannenbaum — Vice President of Investor Relations…